The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Early MRD negativity predicts depth of response to CAR T-cells in R/R MM
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial used the CAR T-cell therapy idecabtagene vicleucel (formerly bb2121) to treat relapsed/refractory multiple myeloma (MM), and yielded deep responses in patients. The most intriguing finding of this study was that measurable residual disease (MRD) negativity was often achieved before traditional response criteria established by the International Myeloma Working Group (IMWG). This quick MRD response implies that the uses of MRD could be expanded in the future. For example, MRD status could be measured early in treatment to predict depth of response.
